• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Hummingbird TTS ear tube system expanded for use in young children

Article

The Hummingbird TTS will make ear procedures much less complicated and expensive, and it is now cleared for children aged 6 months and above.

The surgical technology company Preceptis Medical recently announced US Food and Drug Administration clearance for expanded uses of the Hummingbird® Tympanostomy Tube System (TTS). This will allow in-office procedures in children aged 6 months and above.

The Hummingbird TTS is used for pediatric ear tube procedures, combining the steps and tools of a standard procedure into a single device. This allows otolaryngologists or ear, nose, and throat specialists (ENTs) in an office setting to make an incision and deliver an ear tube with a single pass. Fasting, general anesthesia, and an operating room will not be necessary with the Hummingbird, which has a 98% success rate in an office environment. Parents can also be present, and only topical anesthetic will be necessary.

“This device has been a gamechanger for patients and families. Having their child’s ear tubes placed in a quick office visit is comforting to parents, and they have been happy with the results. We look forward to offering this procedure to even more eligible patients,” said Nathan Page, MD, pediatric otolaryngologist at Phoenix Children’s Hospital.

The Hummingbird could save thousands of dollars per patient, across about one million children that undergo ear tube procedures a year. Launch plans from Preceptis Medical were a success, and the company will continue this momentum to expand accessibility of the Hummingbird even further.

“Our goal when we started Preceptis was to provide a safe, simple, and less expensive ear tube procedure option to all families. This final label expansion represents the work of many ENTs, clinical study coordinators, and team members, and I appreciate the trust parents put into Preceptis and our ENTs while participating in the study,” said Steve Anderson, CEO, Preceptis Medical.

Reference

Preceptis Medical receives FDA clearance for expanded labeling for Hummingbirdsystem. Business Wire. August 15, 2022. Accessed August 18, 2022. https://www.businesswire.com/news/home/20220815005100/en/Preceptis-Medical-Receives-FDA-Clearance-for-Expanded-Labeling-for-Hummingbird-System

Related Videos
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Scott Ceresnak, MD
Scott Ceresnak, MD
Importance of maternal influenza vaccination recommendations
Reducing HIV reservoirs in neonates with very early antiretroviral therapy | Deborah Persaud, MD
Samantha Olson, MPH
Deborah Persaud, MD
Ari Brown, MD, FAAP | Pediatrician and CEO of 411 Pediatrics; author, baby411 book series; chief medical advisor, Kabrita USA.
© 2024 MJH Life Sciences

All rights reserved.